Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120
- PMID: 2455898
- PMCID: PMC281716
- DOI: 10.1073/pnas.85.14.5200
Human immunodeficiency virus type 1 challenge of chimpanzees immunized with recombinant envelope glycoprotein gp120
Abstract
The major envelope glycoprotein, gp120, of human immunodeficiency virus type 1 (HIV-1) was purified from a Chinese hamster ovary cell line transfected with a truncated form of the HIV-1 env gene. The recombinant glycoprotein (rgp120) was formulated with aluminum hydroxide adjuvant and was used to immunize chimpanzees. The recombinant preparation was effective in eliciting cellular and humoral immunity as well as immunologic memory. Anti-rgp 120 antibodies reacted with authentic viral gp120 in immunological blot assays and were able to neutralize HIV-1 infectivity in vitro. Sera from the rgp120-immunized animals were able to neutralize HIV-1 pseudotypes of vesicular stomatitis virus prepared from the IIIB isolate, from which the gene encoding rgp120 was derived, as well as two heterologous isolates, ARV-2 and RF. The immune response elicited against the rgp120 was not effective in preventing viral infection after intravenous challenge with HIV-1. The implications of these results on HIV-1 vaccine development are discussed.
Similar articles
-
Polyvalent human immunodeficiency virus synthetic immunogen comprised of envelope gp120 T helper cell sites and B cell neutralization epitopes.J Immunol. 1989 May 15;142(10):3612-9. J Immunol. 1989. PMID: 2469721
-
Specific cellular immune response and neutralizing antibodies in goats immunized with native or recombinant envelope proteins derived from human T-lymphotropic virus type IIIB and in human immunodeficiency virus-infected men.Proc Natl Acad Sci U S A. 1987 Jul;84(14):4994-8. doi: 10.1073/pnas.84.14.4994. Proc Natl Acad Sci U S A. 1987. PMID: 2440037 Free PMC article.
-
Challenge of chimpanzees (Pan troglodytes) immunized with human immunodeficiency virus envelope glycoprotein gp120.J Virol. 1989 Dec;63(12):5046-53. doi: 10.1128/JVI.63.12.5046-5053.1989. J Virol. 1989. PMID: 2555541 Free PMC article.
-
Serological responses in chimpanzees inoculated with human immunodeficiency virus glycoprotein (gp120) subunit vaccine.Proc Natl Acad Sci U S A. 1987 Dec;84(23):8583-7. doi: 10.1073/pnas.84.23.8583. Proc Natl Acad Sci U S A. 1987. PMID: 3479807 Free PMC article.
-
Protection of MN-rgp120-immunized chimpanzees from heterologous infection with a primary isolate of human immunodeficiency virus type 1.J Infect Dis. 1996 Jan;173(1):52-9. doi: 10.1093/infdis/173.1.52. J Infect Dis. 1996. PMID: 8537682
Cited by
-
Vaccine protection against simian immunodeficiency virus infection.Proc Natl Acad Sci U S A. 1989 Aug;86(16):6353-7. doi: 10.1073/pnas.86.16.6353. Proc Natl Acad Sci U S A. 1989. PMID: 2548210 Free PMC article.
-
Inactivated simian immunodeficiency virus vaccine failed to protect rhesus macaques from intravenous or genital mucosal infection but delayed disease in intravenously exposed animals.J Virol. 1990 May;64(5):2290-7. doi: 10.1128/JVI.64.5.2290-2297.1990. J Virol. 1990. PMID: 2157886 Free PMC article.
-
New FDA drug approval policies and HIV vaccine development.Am J Public Health. 1990 Mar;80(3):336-41. doi: 10.2105/ajph.80.3.336. Am J Public Health. 1990. PMID: 2305921 Free PMC article.
-
Human monoclonal antibodies to the human immunodeficiency virus type 1 (HIV-1) transmembrane glycoprotein gp41 enhance HIV-1 infection in vitro.Proc Natl Acad Sci U S A. 1990 Apr;87(8):3185-9. doi: 10.1073/pnas.87.8.3185. Proc Natl Acad Sci U S A. 1990. PMID: 2326277 Free PMC article.
-
Antibody-mediated in vitro neutralization of human immunodeficiency virus type 1 abolishes infectivity for chimpanzees.J Virol. 1990 Aug;64(8):3674-8. doi: 10.1128/JVI.64.8.3674-3678.1990. J Virol. 1990. PMID: 2370678 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical